Real-world outcomes of axi-cel treatment of large B-cell lymphoma
In this MEDtalk, Dr. Frederick L. Locke presents real-world evidence of axi-cel in the treatment of patients with large B-cell lymphoma. Focusing on the impact of age and comorbidity status on safety and efficacy outcomes after axi-cel infusion, Dr Locke highlights that even though age does not predict for worse efficacy of axi-cell, older patients (≥ 65 years) should be treated with caution, as they are more likely to have adverse events.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.